What is Polaryx Therapeutics, Inc. 's cash & equivalents?

Polaryx Therapeutics, Inc. (PLYX) reported cash & equivalents of $3.08M in Q1 2026.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Polaryx Therapeutics, Inc. PLYX Cash & Equivalents

Cash & Equivalents at other companies

BioMarin PharmaceuticalsBMRN

$3.07B+193%

Zevra Therapeutics, Inc.ZVRA

$95.6M+156%

Eton Pharmaceuticals, Inc.ETON

$19.66M+12.9%

XER

Xeris Biopharma Holdings, Inc.XERS

$111.75M+91.2%

Relay Therapeutics, Inc.RLAY

$204.59M+119%

PVL

Palvella TherapeuticsPVLA

$206.39M+173%

Other financials

Income statement

See full

Operating income-$2.0M+61.2%

Net income-$2.5M+49.6%

EPS (diluted)-$0.05+54.5%

Balance sheet

See full

Total equity$2.5M-41.5%

Total assets$3.5M—

Cash flow

See full

Operating cash flow-$2.1M-191%

Valuation

See full

Market cap$132.59M-87.6%

Returns & leverage

See full

Return on equity-1,209.8%—

Current ratio3.5×—

Where this comes from

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Polaryx Therapeutics, Inc. ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Polaryx Therapeutics, Inc. 's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Polaryx Therapeutics, Inc. 's cash & equivalents?: Polaryx Therapeutics, Inc. (PLYX) reported cash & equivalents of $3.08M in Q1 2026.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.